Ticagrelor
- TRADE NAME: Brilinta (AstraZeneca)
- INDICATIONS: Thrombotic cardiovascular events
- CLASS: Antiplatelet, Antiplatelet; cyclopentyl triazolo-pyrimidine (CPTP)
- HALF-LIFE: 7 hours
FDA APPROVAL DATE: 07/20/2011
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Atazanavir, Carbamazepine, Clarithromycin, Dexamethasone, Digoxin, Efavirenz, Indinavir, Inotersen, Itraconazole, Ketoconazole, Lovastatin, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Rifampin, Ritonavir, Saquinavir, Simvastatin, Telithromycin, Venetoclax, Voriconazole
PREGNANCY CATEGORY: C
Maintenance doses of aspirin above 100 mg reduce the effectiveness of ticagrelor and should be avoided.
Contra-indicated in patients with a history of intracranial hemorrhage, or active pathological bleeding, and in patients with severe hepatic impairment.
BLEEDING RISK
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 03/13/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric